Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.

Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A; BRAGGSS.

Ann Rheum Dis. 2016 May 31. pii: annrheumdis-2015-208849. doi: 10.1136/annrheumdis-2015-208849. [Epub ahead of print]

2.

Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.

Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators.

Arthritis Rheumatol. 2015 May;67(8):2011-9. doi: 10.1002/art.39169. Erratum in: Arthritis Rheumatol. 2015 Nov;67(11):3096.

3.

Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.

Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Eyre S, Churchman SM, Wilson AG, Isaacs JD, Hyrich K, Barton A, Plant D, Savic S, Cook GP, Sarzi-Puttini P, Emery P, Barrett JH, Morgan AW, McDermott MF.

Ann Rheum Dis. 2014 Jun;73(6):1202-10. doi: 10.1136/annrheumdis-2013-203276. Epub 2013 May 17.

PMID:
23687262
4.

High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis.

Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister K, Amos CI, Padyukov L, Toes RE, Huizinga TW, Wijmenga C, Trynka G, Franke L, Westra HJ, Alfredsson L, Hu X, Sandor C, de Bakker PI, Davila S, Khor CC, Heng KK, Andrews R, Edkins S, Hunt SE, Langford C, Symmons D; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate; Wellcome Trust Case Control Consortium, Concannon P, Onengut-Gumuscu S, Rich SS, Deloukas P, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Ärlsetig L, Martin J, Rantapää-Dahlqvist S, Plenge RM, Raychaudhuri S, Klareskog L, Gregersen PK, Worthington J.

Nat Genet. 2012 Dec;44(12):1336-40. doi: 10.1038/ng.2462. Epub 2012 Nov 11.

5.

Heterogeneity of anticitrullinated peptide antibodies and response to anti-tumor necrosis factor agents in rheumatoid arthritis.

Fisher BA, Plant D, Lundberg K, Charles P, Barton A, Venables PJ; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS).

J Rheumatol. 2012 May;39(5):929-32. doi: 10.3899/jrheum.111315. Epub 2012 Apr 1.

PMID:
22467927
6.

Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis.

Hassan B, Maxwell JR, Hyrich KL; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG.

Rheumatology (Oxford). 2010 Jan;49(1):43-7. doi: 10.1093/rheumatology/kep372. Epub 2009 Nov 19.

7.

A study of the prevalence of systemic sclerosis in northeast England.

Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths ID.

Rheumatology (Oxford). 2004 May;43(5):596-602. Epub 2004 Feb 10. Review.

8.

Acute and long-term management of patients with vertebral fractures.

Francis RM, Baillie SP, Chuck AJ, Crook PR, Dunn N, Fordham JN, Kelly C, Rodgers A.

QJM. 2004 Feb;97(2):63-74. Review.

9.

Management of osteoporosis in patients with hip fractures.

Francis RM, Baillie SP, Chuck AJ, Crook PR, Daymond T, Dunn N, Fordham JN, Kelly C, Rodgers A.

QJM. 2000 Aug;93(8):501-6. Review. No abstract available.

10.

[Rheumatoid arthritis and recurrent rheumatism associated with sclerosing cholangitis].

Sykes HR, Deighton CM, Chuck AJ, Crook PR.

Rev Rhum Ed Fr. 1994 Jun;61(6):456-8. French.

PMID:
7833872
11.

Low dose total-body irradiation.

Crook PR, Lucraft HH, Evans RG, Griffiths HD.

Br J Radiol. 1988 Jan;61(721):94. No abstract available.

PMID:
3280065
12.

Costs of providing a rheumatological service.

Bedi S, Crook PR, Dick WC, Griffiths ID, Platt PN.

Br J Rheumatol. 1987 Dec;26(6):454-7.

PMID:
3690141
13.

Lack of effect of total body irradiation in rheumatoid arthritis.

Crook PR, Lucraft HH, Evans RG, Griffiths ID.

Br J Rheumatol. 1986 Nov;25(4):384-7.

PMID:
3535983
14.

Report on chloroquine and dapsone in the treatment of rheumatoid arthritis: a 6-month comparative study.

Fowler PD, Shadforth MF, Crook PR, Lawton A.

Ann Rheum Dis. 1984 Apr;43(2):200-4.

15.

Acetylator phenotype and the effect of dapsone in rheumatoid arthritis.

Crook PR, Hortas C, Roberts EJ, Swinson DR, Mucklow JC, Shadforth MF.

J Rheumatol. 1983 Oct;10(5):805-8.

PMID:
6644705
16.
17.

Bacteroides causing osteomyelitis in rheumatoid arthritis.

Crook PR, Gray J.

Ann Rheum Dis. 1982 Dec;41(6):645-6. No abstract available.

18.

Diclofenac sodium and thyroid function tests.

Fowler PD, Crook PR, Hothersall TE.

Rheumatol Rehabil. 1982 Feb;21(1):42-7. No abstract available.

PMID:
7036321
19.

The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease.

Crook PR, Willis JV, Kendall MJ, Jack DB, Fowler PD.

Eur J Clin Pharmacol. 1982;21(4):331-4.

PMID:
7056279
20.

Errors in prescribing dapsone.

Crook PR, Fowler PD, Shadforth MF.

Lancet. 1981 Oct 3;2(8249):760. No abstract available.

PMID:
6116898
Items per page

Supplemental Content

Loading ...
Write to the Help Desk